B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

KCNMB2

MOLECULAR TARGET

potassium calcium-activated channel subfamily M regulatory beta subunit 2

UniProt: Q9Y691NCBI Gene: 1024232 compounds

KCNMB2 (potassium calcium-activated channel subfamily M regulatory beta subunit 2) is targeted by 32 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting KCNMB2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Nisoldipine1.393
2Thioridazine1.393
3Budesonide1.102
4Thyroxine1.102
5pterostilbene1.102
6Resveratrol1.102
7Fluocinolone Acetonide1.102
8Latanoprost1.102
9Nortriptyline1.102
10Promethazine1.102
11Ritonavir1.102
12Thyroxine1.102
13Simvastatin0.691
14Amdinocillin0.691
15Aminolevulinic Acid0.691
16Amoxapine0.691
17Artemether0.691
18Carvedilol0.691
19Cetirizine0.691
20Ethinyl Estradiol0.691
21Ethylestrenol0.691
22Ezetimibe0.691
23Irbesartan0.691
24Lovastatin0.691
25nafadotride0.691
26Nicardipine0.691
273',4'-didemethylnobiletin [Supplementary Concept]0.691
28Oxcarbazepine0.691
29Pemoline0.691
30Perphenazine0.691
31Tocainide0.691
32Ursodeoxycholic Acid0.691

About KCNMB2 as a Drug Target

KCNMB2 (potassium calcium-activated channel subfamily M regulatory beta subunit 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 32 compounds with documented KCNMB2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

KCNMB2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.